Clinical review of once-daily beclomethasone dipropionate for seasonal allergic rhinitis.
A new double-strength (84 micrograms/spray) formulation of beclomethasone dipropionate (BDP-ds) as an aqueous suspension has been introduced to control symptoms of allergic rhinitis with once-daily intranasal dosing. This paper reviews the results of three clinical reports which show that BDP-ds given once a day is more effective than placebo and as effective as regular-strength beclomethasone dipropionate given twice daily in reducing the nasal symptoms of seasonal allergic rhinitis. Symptom improvement was seen within 2 days of treatment initiation and was maintained for the subsequent 4 weeks. BDP-ds was found to be as safe and well tolerated as placebo. Adverse effects, which were generally mild, included headache, nasal burning/irritation, epistaxis, coughing, and pharyngitis. BDP-ds is safe for children as young as 6 years of age, and its once-daily dosing schedule may improve patient compliance.
Chervinsky
P
P
Allergy Associates, Inc., New England Research Center, North Dartmouth, Massachusetts, USA.
D000281:Administration, Intranasal; D000328:Adult; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004361:Drug Tolerance; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D005938:Glucocorticoids; D001507:Beclomethasone